2026 annual financial data
Immunovant 2026 Operating margin
Immunovant 2026 operating margin with verified reported values.
Direct answer
Operating margin was Not calculable.
Operating income was -532,902,000 USD and net income was -505,606,000 USD.
Operating cash flow was -407,310,000 USD.
Get free Immunovant email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -532,902,000 USD
- Net income
- -505,606,000 USD
- Operating cash flow
- -407,310,000 USD